1e
19
1
49
2
2
18
1b
1d
18
34
5a
1d
2 29
1d
25
Vandana Batra, MBBS,MD
88
5a
Associate Professor of Clinical Pediatrics (Oncology)
7
61
Department: Pediatrics
4
1
b
1d
46
Contact information
51
4
3
3
3
2
29
4
b
1f
51
Children's Hospital of Philadelphia
2b The HUB for Clinical Collaboration
20 Office 3526, Third Floor
3e 3500 Civic Center Boulevard
Philadelphia, PA 19104
26
2b The HUB for Clinical Collaboration
20 Office 3526, Third Floor
3e 3500 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 267-226-7360
30
7f
30
Email:
BATRAV@chop.edu
12
BATRAV@chop.edu
13
Education:
21 9 MBBS c
4f Lady Hardinge Medical College (LHMC), New Delhi, India, 1992.
21 7 MD 17 (Pediatrics) c
4e Maulana Azad Medical College (MAMC), New Delhi, India, 1996.
c
3
3
3
3
8d
Permanent link21 9 MBBS c
4f Lady Hardinge Medical College (LHMC), New Delhi, India, 1992.
21 7 MD 17 (Pediatrics) c
4e Maulana Azad Medical College (MAMC), New Delhi, India, 1996.
c
2 29
21
1e
1d
24
5e
1d Desmoid Fibromatosis
15 Neuroblastoma
13 Solid Tumors
62
65
e 29
27
Description of Clinical Expertise
22 Germ Cell Tumors1d Desmoid Fibromatosis
15 Neuroblastoma
13 Solid Tumors
62
Description of Other Expertise
39 Quality Improvement in Pediatric Oncology65
Description of Research Expertise
25 Targeted Radiotherapye 29
23
61 Adeline T Yang MD MS,Lisa States MD, Vandana Batra MD 52 : The role of fluorine 18 Fluorodeoxyglucose positron emission tomography c5 (18F FDG PET) in therapeutic decision making for pediatric malignant germ cell tumors.' Magic Meeting, Asilomar Conference Grounds, Pacific Grove, CA May 2025 Notes: Poster.
19f Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. : Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood and Cancer. Oct 2023 Notes: DOI: 10.1002/pbc.30743 2a Online ahead of print.
1a0 Hill-Kayser CE, Li Y, Kurtz G, Mattei P, Balis F, Lustig RA, LaRiviere M, MacFarland S, Batra V, Mosse Y, Maris JM, Balamuth N, Bagatell R: Survival and local recurrence risk in patients with high-risk neuroblastoma treated with proton therapy over a 10 year interval. American Society for Radiation Oncology Annual Meeting, San Diego, CA Oct 2023 Notes: Poster 14
201 Christine Hill-Kayser, Goldie Kurtz, Naomi Balamuth, Robert Lustig, Frank Balis, Suzanne Macfarland, Vandana Batra, Yael P. Mosse, John M. Maris, Sogol Mostoufi-Moab, Jill Ginsberg, Rochelle Bagatell: Efficacy & Toxicity of External Beam Radiotherapy (EBRT) for Metastatic Sites (MS) in Patients with High-Risk Neuroblastoma (HR-NBL). International Society of Pediatric Oncology, 55th Annual Congress, Ottawa, Canada Oct 2023 Notes: Poster.
17a Kaoru Takasaki MD, Laura A.T. Kagami MD, Collen Croy PharmD, Jason L. Freedman MD, MSCE, Benjamin L. Laskin MD, Bridget Rauch BA, Anne Reilly MD, David H. Rhodes BSN, RN, Jennifer Stundon MD, PhD, Julie Vardaro MHA, Vandana Batra, MD: Improving guideline-concordant care for tumor lysis syndrome in pediatric oncology patients. 71 American Society of Pediatric Hematology/Oncology Annual Conference, Fort Worth, TX May 2023 Notes: Poster 14
1e4 Micky K. Bacchus, BS; David S. Anderson, MD; Esther R. Berko, MD, PhD; Lisa J. States, MD; Rochelle Bagatell, MD; Sarah E. Hopkins, MD, MSPH; Vandana Batra, MD.: Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments. Journal of Pediatric Hematology/Oncology 45(3): 152-154, April 2023 Notes: DOI: 10.1097/MPH.0000000000002643.
22f Mehran Makvandi, Minu Samanta, Paul Martorano, Hwan Lee, Sarah B. Gitto, Khushbu Patel, David Groff, Jennifer Pogoriler, Daniel Martinez, Aladdin Riad, Hannah Dabagian, Michael Zaleski, Tara Taghvaee, Kuiying Xu, Ji Youn Lee, Catherine Hou, Alvin Farrel, Vandana Batra, Sean D. Carlin, Daniel J. Powell Jr, Robert H. Mach, Daniel A. Pryma & John M. Maris : Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. Communications Biology 5(1): 1260, Nov 2022.
1b1 Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J, Ranieri P, Tsang M, Hou C, Li Y, Pawel B, Martinez D, Vaidyanathan G, Carlin S, Pryma DA, Maris JM.: Preclinical development of [211At]meta-astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma. Clinical Cancer Research 28(18): 4146-4157, Sep 2022.
12a Batra V: Meta-[211At]astatobenzylguanidine ([211At]MABG) increases overall survival in a preclinical model of disseminated neuroblastoma. Advances in Neuroblastoma Research Conference, Virtual Jan 2021 Notes: Digital Poster.
2c
7
1d
1f
Selected Publications
d7 Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Farwell MD.: PARP1-targeted alpha therapy enhances target expression. EJNMMI Res 26 15(63), Jun 2025.61 Adeline T Yang MD MS,Lisa States MD, Vandana Batra MD 52 : The role of fluorine 18 Fluorodeoxyglucose positron emission tomography c5 (18F FDG PET) in therapeutic decision making for pediatric malignant germ cell tumors.' Magic Meeting, Asilomar Conference Grounds, Pacific Grove, CA May 2025 Notes: Poster.
19f Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. : Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood and Cancer. Oct 2023 Notes: DOI: 10.1002/pbc.30743 2a Online ahead of print.
1a0 Hill-Kayser CE, Li Y, Kurtz G, Mattei P, Balis F, Lustig RA, LaRiviere M, MacFarland S, Batra V, Mosse Y, Maris JM, Balamuth N, Bagatell R: Survival and local recurrence risk in patients with high-risk neuroblastoma treated with proton therapy over a 10 year interval. American Society for Radiation Oncology Annual Meeting, San Diego, CA Oct 2023 Notes: Poster 14
201 Christine Hill-Kayser, Goldie Kurtz, Naomi Balamuth, Robert Lustig, Frank Balis, Suzanne Macfarland, Vandana Batra, Yael P. Mosse, John M. Maris, Sogol Mostoufi-Moab, Jill Ginsberg, Rochelle Bagatell: Efficacy & Toxicity of External Beam Radiotherapy (EBRT) for Metastatic Sites (MS) in Patients with High-Risk Neuroblastoma (HR-NBL). International Society of Pediatric Oncology, 55th Annual Congress, Ottawa, Canada Oct 2023 Notes: Poster.
17a Kaoru Takasaki MD, Laura A.T. Kagami MD, Collen Croy PharmD, Jason L. Freedman MD, MSCE, Benjamin L. Laskin MD, Bridget Rauch BA, Anne Reilly MD, David H. Rhodes BSN, RN, Jennifer Stundon MD, PhD, Julie Vardaro MHA, Vandana Batra, MD: Improving guideline-concordant care for tumor lysis syndrome in pediatric oncology patients. 71 American Society of Pediatric Hematology/Oncology Annual Conference, Fort Worth, TX May 2023 Notes: Poster 14
1e4 Micky K. Bacchus, BS; David S. Anderson, MD; Esther R. Berko, MD, PhD; Lisa J. States, MD; Rochelle Bagatell, MD; Sarah E. Hopkins, MD, MSPH; Vandana Batra, MD.: Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments. Journal of Pediatric Hematology/Oncology 45(3): 152-154, April 2023 Notes: DOI: 10.1097/MPH.0000000000002643.
22f Mehran Makvandi, Minu Samanta, Paul Martorano, Hwan Lee, Sarah B. Gitto, Khushbu Patel, David Groff, Jennifer Pogoriler, Daniel Martinez, Aladdin Riad, Hannah Dabagian, Michael Zaleski, Tara Taghvaee, Kuiying Xu, Ji Youn Lee, Catherine Hou, Alvin Farrel, Vandana Batra, Sean D. Carlin, Daniel J. Powell Jr, Robert H. Mach, Daniel A. Pryma & John M. Maris : Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. Communications Biology 5(1): 1260, Nov 2022.
1b1 Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J, Ranieri P, Tsang M, Hou C, Li Y, Pawel B, Martinez D, Vaidyanathan G, Carlin S, Pryma DA, Maris JM.: Preclinical development of [211At]meta-astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma. Clinical Cancer Research 28(18): 4146-4157, Sep 2022.
12a Batra V: Meta-[211At]astatobenzylguanidine ([211At]MABG) increases overall survival in a preclinical model of disseminated neuroblastoma. Advances in Neuroblastoma Research Conference, Virtual Jan 2021 Notes: Digital Poster.
2c